Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Gross Profit: 2022-2025

Historic Gross Profit for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $1.7 million.

  • InMed Pharmaceuticals' Gross Profit fell 18.29% to $403,159 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 2.75%. This contributed to the annual value of $1.7 million for FY2025, which is 55.02% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Gross Profit stood at $1.7 million for FY2025, which was up 55.02% from $1.1 million recorded in FY2024.
  • InMed Pharmaceuticals' Gross Profit's 5-year high stood at $1.7 million during FY2025, with a 5-year trough of $543,546 in FY2022.
  • For the 3-year period, InMed Pharmaceuticals' Gross Profit averaged around $1.4 million, with its median value being $1.4 million (2023).
  • Per our database at Business Quant, InMed Pharmaceuticals' Gross Profit spiked by 158.13% in 2023 and then decreased by 21.53% in 2024.
  • Yearly analysis of 4 years shows InMed Pharmaceuticals' Gross Profit stood at $543,546 in 2022, then spiked by 158.13% to $1.4 million in 2023, then declined by 21.53% to $1.1 million in 2024, then spiked by 55.02% to $1.7 million in 2025.